3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Vascular Diseases
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Recurrence
1
Pathologic Processes
1
Paraproteinemias
1
Neoplastic Processes
1
Neoplasms, Plasma Cell
1
Neoplasms, Glandular and Epithelial
1
Multiple Myeloma
1
Mullerian Mixed Tumor of Ovary
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Lung Diseases
1
Liver Neoplasms
1
Liver Diseases
1
Leukemia, Myeloid, Acute
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Digestive System Neoplasms
1
Interventions
dacetuzumab
6
Rituximab
6
blinatumomab
4
ibrutinib
3
Ifosfamide
3
Bortezomib
3
ponatinib
2
cobomarsen
2
Vorinostat
2
Lenalidomide
2
Etoposide
2
Dexamethasone
2
Carboplatin
2
tetulomab tetraxetan lu-177
1
pegaspargase
1
ficlatuzumab
1
enzalutamide
1
durvalumab
1
cirmtuzumab
1
asparaginase erwinia chrysanthemi recombinant
1
acalabrutinib
1
Vincristine
1
Prednisone
1
Methotrexate
1
Lutetium
1
KW-2478
1
Imatinib Mesylate
1
Hsp90 inhibitor KU757
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Immunoproliferative Disorders
×
ficlatuzumab
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled